A U.S. appeals court upholds a lower court ruling in favor of Pozen (POZN -0.8%) against Par...

A U.S. appeals court upholds a lower court ruling in favor of Pozen (POZN-0.8%) against Par Pharmaceutical (PRX), Alphapharm and Dr. Reddy’s Laboratories (RDY+1.9%), affirming the district court's earlier decision that found POZN's patent valid, and blocked PRX and RDY from selling a generic version of POZN's migraine drug Treximet until 2025.